Biomarkers like PD-L1 expression, tumor mutation burden (TMB), and microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) status are shown to be effective in forecasting antitumor effectiveness and potential toxicities of ICIs [249,250,251]. The gene discussed is CD274; the disease is neoplasm.